JP2009510044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510044A5 JP2009510044A5 JP2008532874A JP2008532874A JP2009510044A5 JP 2009510044 A5 JP2009510044 A5 JP 2009510044A5 JP 2008532874 A JP2008532874 A JP 2008532874A JP 2008532874 A JP2008532874 A JP 2008532874A JP 2009510044 A5 JP2009510044 A5 JP 2009510044A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- inflammatory
- allergic
- methyl
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000124008 Mammalia Species 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 238000011200 topical administration Methods 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- IEAAPZQFLDBHCF-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methyl-1,2-oxazole-5-carboxamide Chemical compound C=1C(C)=NOC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 IEAAPZQFLDBHCF-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- -1 tetrahydro-2H-pyran-4-ylamino Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72159705P | 2005-09-29 | 2005-09-29 | |
| PCT/GB2006/003627 WO2007036734A1 (en) | 2005-09-29 | 2006-09-29 | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510044A JP2009510044A (ja) | 2009-03-12 |
| JP2009510044A5 true JP2009510044A5 (enExample) | 2009-11-05 |
Family
ID=37685723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532874A Pending JP2009510044A (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
| JP2008532873A Expired - Fee Related JP5323484B2 (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532873A Expired - Fee Related JP5323484B2 (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090131431A1 (enExample) |
| EP (2) | EP1940835B1 (enExample) |
| JP (2) | JP2009510044A (enExample) |
| AT (1) | ATE503756T1 (enExample) |
| DE (1) | DE602006021044D1 (enExample) |
| ES (1) | ES2363795T3 (enExample) |
| WO (2) | WO2007036734A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
| GB0614570D0 (en) * | 2006-07-21 | 2006-08-30 | Glaxo Group Ltd | Compounds |
| NZ574533A (en) | 2006-08-01 | 2011-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| SI2124944T1 (sl) | 2007-03-14 | 2012-05-31 | Ranbaxy Lab Ltd | Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze |
| WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
| EP2249646A4 (en) * | 2008-02-06 | 2013-09-25 | Glaxo Group Ltd | PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN |
| WO2009100170A1 (en) * | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| EP2346867A1 (en) * | 2008-09-19 | 2011-07-27 | Ranbaxy Laboratories Limited | Phosphodiestarase inhibitors |
| CA2749403A1 (en) | 2009-01-13 | 2010-09-02 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
| EP2547664B1 (de) * | 2010-03-16 | 2016-05-04 | Merck Patent GmbH | Morpholinylchinazoline |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| WO2012061926A1 (en) * | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| EP2574607A1 (en) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US20160031907A1 (en) * | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| DE102014009164A1 (de) * | 2014-06-03 | 2015-12-03 | Herbalist & Doc Gesundheitsgesellschaft Mbh | Silikonölhaltige nasal anzuwendende Formulierungen |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US20200087271A1 (en) | 2016-12-20 | 2020-03-19 | Syngenta Participations Ag | N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity |
| MA49014A (fr) * | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| TW201920188A (zh) * | 2017-08-10 | 2019-06-01 | 美商美國禮來大藥廠 | [1,2,4]三唑衍生物 |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP7677983B2 (ja) * | 2020-01-23 | 2025-05-15 | マイオフォルテ セラピューティクス，インク． | Ｐｇｄｈ阻害剤、およびその作製と使用の方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314392A (pt) * | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
-
2006
- 2006-09-29 US US12/067,990 patent/US20090131431A1/en not_active Abandoned
- 2006-09-29 WO PCT/GB2006/003627 patent/WO2007036734A1/en not_active Ceased
- 2006-09-29 JP JP2008532874A patent/JP2009510044A/ja active Pending
- 2006-09-29 DE DE602006021044T patent/DE602006021044D1/de active Active
- 2006-09-29 WO PCT/GB2006/003626 patent/WO2007036733A1/en not_active Ceased
- 2006-09-29 AT AT06779578T patent/ATE503756T1/de not_active IP Right Cessation
- 2006-09-29 EP EP06779578A patent/EP1940835B1/en active Active
- 2006-09-29 JP JP2008532873A patent/JP5323484B2/ja not_active Expired - Fee Related
- 2006-09-29 ES ES06779578T patent/ES2363795T3/es active Active
- 2006-09-29 EP EP06779579A patent/EP1940836A1/en not_active Withdrawn
- 2006-09-29 US US12/067,994 patent/US20080255186A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2018513107A5 (enExample) | ||
| CN102316863B (zh) | 5-苄基氨基水杨酸衍生物或其盐的医药用途 | |
| JP2013526609A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2012520249A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
| JP2005506370A5 (enExample) | ||
| RU2015117267A (ru) | Замещенные соединения амида | |
| JP2013542261A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2005539012A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2015515985A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| JP2010529969A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| JP2015508765A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| JP7667764B2 (ja) | 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物 | |
| JP2013516475A5 (enExample) |